CD19 and acute myeloid leukemia: Poor solubility, short half‐life, and require repeated doses result in limitations on clinical application to achieve its therapeutic activity.[43] In this article, our BiTE is structurally similar to Blinatumomab, which been previously reported.[44] Blinatumomab, a CD19/CD3 BiTE designed in the BiTE (bispecific T‐cell engager) format, is approved by the US Food and Drug Administration for the treatment of relapsed or refractory B‐cell precursor AML.